机构:[1]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China[2]Department of Encephalopathy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China大德路总院脑病科广东省中医院[3]Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, Pre-Incubator for Innovative Drugs & Medicine, School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China[4]Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
Alzheimer's disease (AD) is a complicated progressive neurodegeneration disorder. To confront AD, scientists are searching for multi-target-directed ligands (MTDLs) to delay disease progression. The in silico prediction of chemical-protein interactions (CPI) can accelerate target identification and drug discovery. Previously, we developed 100 binary classifiers to predict the CPI for 25 key targets against AD using the multi-target quantitative structureactivity relationship (mt-QSAR) method. In this investigation, we aimed to apply the mtQSAR method to enlarge the model library to predict CPI towards AD. Another 104 binary classifiers were further constructed to predict the CPI for 26 preclinical AD targets based on the naive Bayesian (NB) and recursive partitioning (RP) algorithms. The internal 5-fold cross-validation and external test set validation were applied to evaluate the performance of the training sets and test set, respectively. The area under the receiver operating characteristic curve (ROC) for the test sets ranged from 0.629 to 1.0, with an average of 0.903. In addition, we developed a web server named AlzhCPI to integrate the comprehensive information of approximately 204 binary classifiers, which has potential applications in network pharmacology and drug repositioning. AlzhCPI is available online at http://rcidm.org/AlzhCPI/index. html. To illustrate the applicability of AlzhCPI, the developed system was employed for the systems pharmacology-based investigation of shichangpu against AD to enhance the understanding of the mechanisms of action of shichangpu from a holistic perspective.
基金:
National Natural Science Foundation of China [81603318, 81673627, 81473740]; CAMS Initiative for Innovative Medicine [2016-I2M-3007]; Guangdong Provincial Major Science and Technology for Special Program of China [2012A080202017]; South China Chinese Medicine Collaborative Innovation Center [A1AFD01514A05]
第一作者机构:[1]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China[2]Department of Encephalopathy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构:[1]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China[2]Department of Encephalopathy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
Fang Jiansong,Wang Ling,Li Yecheng,et al.AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease[J].PLOS ONE.2017,12(5):doi:10.1371/journal.pone.0178347.
APA:
Fang, Jiansong,Wang, Ling,Li, Yecheng,Lian, Wenwen,Pang, Xiaocong...&Du, Guan-Hua.(2017).AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease.PLOS ONE,12,(5)
MLA:
Fang, Jiansong,et al."AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease".PLOS ONE 12..5(2017)